Dr. O'Donnell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
450 Brookline Ave
Boston, MA 02215Phone+1 617-632-3000
Education & Training
Brigham and Women's Hospital/Massachusetts General Hospital/Dana-Farber Cancer InstituteFellowship, Hematology and Medical Oncology, 2010 - 2014
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2007 - 2010
Vanderbilt University School of MedicineClass of 2007
Certifications & Licensure
FL State Medical License 2024 - Present
NH State Medical License 2024 - 2026
MA State Medical License 2009 - 2025
ME State Medical License 2020 - 2025- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
Publications & Presentations
PubMed
- 674 citationsCiltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CART...Jesus G. Berdeja, Deepu Madduri, Saad Z. Usmani, Andrzej Jakubowiak, Mounzer Agha
Lancet. 2021-07-24 - 80 citationsRicolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.Yuko Mishima, Loredana Santo, Homare Eda, Diana Cirstea, Neeharika Nemani
British Journal of Haematology. 2015-05-01 - 106 citationsA Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone in Transplant-Ineligible Multiple MyelomaElizabeth O'Donnell, Jacob P. Laubach, Andrew Yee, Tianqi Chen, Carol Ann Huff
British Journal of Haematology. 2018-07-01
Abstracts/Posters
- Defining the Differentiation States of Multiple Myeloma at Single Cell Resolution Reveals Opportunities for ImmunotherapyElizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Circulating Tumor DNA in the Peripheral Blood As Early Predictor of Clinical Outcome in Relapsed/ Refractory Multiple MyelomaElizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple MyelomaElizabeth K. O'Donnell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Vail Symposium Kicks off Summer Season with Program in Conjunction with Shaw Cancer CenterMay 23rd, 2018
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
